A new clinical trial has demonstrated that a virtual, sustained smoking cessation program can double quit rates among cancer patients compared to standard care. Published in JAMA Network Open, the study found that personalized, long-term support delivered remotely significantly improves outcomes for individuals navigating cancer treatment, addressing a critical gap in oncology care.
Clinical Trial Results and Methodology
Researchers from the University of Texas MD Anderson Cancer Center conducted a randomized clinical trial involving 558 participants who were current smokers and undergoing cancer treatment. Patients were divided into two groups: one receiving standard care—which typically includes brief advice from a physician—and another receiving a comprehensive, proactive, and virtual cessation program.
The intervention group received a six-month, technology-enabled program that included automated text messaging, access to a dedicated tobacco treatment specialist, and evidence-based cessation medications. According to the study, 13.5% of patients in the intervention group successfully quit smoking by the six-month mark, compared to just 6.4% of those who received standard care.
Why Sustained Virtual Support Matters
Smoking cessation is a critical component of cancer care, as continued tobacco use can interfere with the efficacy of treatments such as radiation and chemotherapy, increase the risk of complications, and elevate the likelihood of cancer recurrence or secondary primary tumors.
The primary advantage of this virtual model is its accessibility. Cancer patients often face significant barriers to attending in-person support sessions, including fatigue, transportation challenges, and demanding treatment schedules. By utilizing a mobile-first approach, the program ensures that patients receive consistent, real-time reinforcement without the need for additional hospital visits. The integration of a tobacco treatment specialist provides the human element necessary for behavioral change, while automated messaging ensures the patient remains engaged throughout the challenging process of nicotine withdrawal.
Comparing Intervention Models
Standard smoking cessation care in oncology settings is often limited to a single conversation between the patient and their oncologist. While this "teachable moment" is valuable, it rarely provides the sustained support required to manage the physiological and psychological dependency associated with nicotine.
| Feature | Standard Care | Virtual Sustained Program |
|---|---|---|
| Duration | Brief, episodic | Six months |
| Delivery | In-person/ad-hoc | Virtual/automated + specialist |
| Quit Rate | 6.4% | 13.5% |
| Engagement | Patient-initiated | Proactive/automated |
Clinical Implications for Oncology
The success of this trial suggests that cancer centers should shift toward more proactive, tech-enabled support systems. Integrating these programs into the standard electronic health record (EHR) workflow can help clinicians identify tobacco users early and automate the referral process.
For patients, the results confirm that quitting smoking—even after a cancer diagnosis—remains one of the most effective ways to improve overall health outcomes and treatment tolerance. Ongoing research will likely focus on how to scale these virtual programs across different healthcare systems and whether the quit rates can be maintained over a longer duration beyond the six-month study period.
Related reading